111 related articles for article (PubMed ID: 14707274)
1. Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.
Gullbo J; Wallinder C; Tullberg M; Lövborg H; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
Mol Cancer Ther; 2003 Dec; 2(12):1331-9. PubMed ID: 14707274
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
Gullbo J; Dhar S; Luthman K; Ehrsson H; Lewensohn R; Nygren P; Larsson R
Anticancer Drugs; 2003 Sep; 14(8):617-24. PubMed ID: 14501383
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.
Larsson R; Dhar S; Ehrsson H; Nygren P; Lewensohn R
Br J Cancer; 1998 Aug; 78(3):328-35. PubMed ID: 9703278
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells.
Hansson J; Lewensohn R; Ringborg U
Anticancer Res; 1991; 11(5):1725-30. PubMed ID: 1768043
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
Gullbo J; Lindhagen E; Bashir-Hassan S; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; De La Torre M; Luthman K; Larsson R
Invest New Drugs; 2004 Nov; 22(4):411-20. PubMed ID: 15292711
[TBL] [Abstract][Full Text] [Related]
6. Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines.
Lewensohn R; Ehrsson H; Hansson J; Ringborg U
Anticancer Res; 1991; 11(1):321-4. PubMed ID: 2018366
[TBL] [Abstract][Full Text] [Related]
7. Selective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide.
Roboz J; Jiang J; Holland JF; Bekesi JG
Cancer Res; 1997 Nov; 57(21):4795-802. PubMed ID: 9354441
[TBL] [Abstract][Full Text] [Related]
8. Differential DNA cross-linking and cytotoxicity in PHA-stimulated human lymphocytes exposed to melphalan, m-L-sarcolysin and peptichemio.
Lewensohn R; Hansson J; Ringborg U; Ehrsson H
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):783-8. PubMed ID: 3653195
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.
Gullbo J; Tullberg M; Våbenø J; Ehrsson H; Lewensohn R; Nygren P; Larsson R; Luthman K
Oncol Res; 2003; 14(3):113-32. PubMed ID: 14760861
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.
Lewensohn R; Fernberg JO; Ehrsson H; Merlini G
Med Oncol Tumor Pharmacother; 1991; 8(4):265-9. PubMed ID: 1820493
[TBL] [Abstract][Full Text] [Related]
11. High anticancer efficacy of L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13) in vivo.
Jiang JD; Zhang H; Li JN; Roboz J; Qiao WB; Holland JF; Bekesi G
Anticancer Res; 2001; 21(3B):1681-9. PubMed ID: 11497247
[TBL] [Abstract][Full Text] [Related]
12. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
Gullbo J; Wickström M; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
J Drug Target; 2003 Jul; 11(6):355-63. PubMed ID: 14668056
[TBL] [Abstract][Full Text] [Related]
13. A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse model.
Dierickx KM; Morandini R; Nguyen TH; Salès F; Kauffmann JM; Ghanem GE
Pigment Cell Melanoma Res; 2008 Aug; 21(4):439-50. PubMed ID: 18627526
[TBL] [Abstract][Full Text] [Related]
14. Derivatives of melphalan designed to enhance drug accumulation in cancer cells.
Kupczyk-Subotkowska L; Tamura K; Pal D; Sakaeda T; Siahaan TJ; Stella VJ; Borchardt RT
J Drug Target; 1997; 4(6):359-70. PubMed ID: 9239576
[TBL] [Abstract][Full Text] [Related]
15. [Enhancement of antineoplastic activity of sarcolysin by the means of transforming it into lipid derivative and incorporating into liposomal membranes containing carbohydrate vector].
Kozlov AM; Korchagina EIu; Vodovozova EL; Bovin NV; Molotkovskiĭ IuL; Syrkin AB
Biull Eksp Biol Med; 1997 Apr; 123(4):439-41. PubMed ID: 9190189
[No Abstract] [Full Text] [Related]
16. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
Wickström M; Johnsen JI; Ponthan F; Segerström L; Sveinbjörnsson B; Lindskog M; Lövborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
Mol Cancer Ther; 2007 Sep; 6(9):2409-17. PubMed ID: 17876040
[TBL] [Abstract][Full Text] [Related]
17. DNA-damage in human cells treated with the closely related alkylating agents peptichemio, m-L-sarcolysin and melphalan.
Ringborg U; Lambert B; Lewensohn R; Turesson I
Eur J Cancer Clin Oncol; 1981 Sep; 17(9):991-6. PubMed ID: 7198989
[No Abstract] [Full Text] [Related]
18. Antitumor activity of sarcolysin containing crosslinked copolymers in mice.
Popov DV
Neoplasma; 1985; 32(3):375-9. PubMed ID: 4022198
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxicity of peptichemio compared to melphalan and meta-DL-sarcolysin.
Morasca L; Erba E
Eur J Cancer (1965); 1980 Aug; 16(8):1105-9. PubMed ID: 7439225
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro.
Ehrsson H; Lewensohn R; Wallin I; Hellström M; Merlini G; Johansson B
Cancer Chemother Pharmacol; 1993; 31(4):265-8. PubMed ID: 8422688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
